SCHEMBL30925553

SCHEMBL30925553

COc1cnc2c(NS(=O)(=O)c3ccc(C)cn3)cccc2c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC40A1 Q9NP59 14/20 0.67
▸ KMT2A Q03164 3/20 0.54
▸ TDP1 Q9NUW8 3/20 0.54
▸ MEN1 O00255 2/20 0.54
▸ LMNA P02545 2/20 0.54
▸ MAPT P10636 2/20 0.54
▸ AGTR1 P30556 2/20 0.54
▸ NPSR1 Q6W5P4 2/20 0.54
▸ TP53 P04637 1/20 0.54
▸ HPGD P15428 1/20 0.54
▸ TSHR P16473 1/20 0.54
▸ CXCR2 P25025 1/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.54
▸ GLO1 Q04760 3/20 0.50
▸ NFKBIA P25963 2/20 0.49
▸ RELA Q04206 2/20 0.49
▸ CKS1B P61024 2/20 0.49
▸ SKP2 Q13309 2/20 0.49
▸ MITF O75030 1/20 0.46
▸ S1PR4 O95977 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27214306 0.88 SLC40A1 (0.77) SLC40A1KMT2ATDP1MEN1LMNA
SCHEMBL30925568 0.88 SLC40A1 (0.77) SLC40A1KMT2ATDP1MEN1LMNA
SCHEMBL30925561 0.85 MEN1 (0.74) SLC40A1KMT2ATDP1MEN1LMNA
SCHEMBL30925487 0.84 SLC40A1 (0.70) SLC40A1KMT2ATDP1MEN1LMNA
SCHEMBL30925536 0.84 SLC40A1 (0.70) SLC40A1KMT2ATDP1MEN1LMNA
SCHEMBL27214164 0.84 SLC40A1 (0.70) SLC40A1KMT2ATDP1MEN1LMNA
SCHEMBL11973663 0.81 SLC40A1 (1.00) SLC40A1KMT2ATDP1MEN1LMNA
SCHEMBL27214187 0.80 SLC40A1 (0.72) SLC40A1KMT2ATDP1MEN1LMNA
SCHEMBL30925433 0.80 SLC40A1 (0.72) SLC40A1KMT2ATDP1MEN1LMNA
SCHEMBL30925548 0.76 SLC40A1 (0.77) SLC40A1KMT2ATDP1MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ZOETIS LLC 2024-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ARSA, MRPS2, SULT2A1 SLC40A1 3357/4885KMT2A 1323/4885TDP1 4247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback